-
Article
Open AccessNeck dissection and post-operative chemotherapy with dimethyl triazeno imidazole carboxamide and cisplatin protocol are useful for oral mucosal melanoma
Oral mucosal melanoma (OMM) is a clinically rare disease with poor prognosis. Various treatment methods have been investigated with the aim of improving the prognosis. This study aimed to analyze the data of a...
-
Article
Open AccessPRAF3 induces apoptosis and inhibits migration and invasion in human esophageal squamous cell carcinoma
Prenylated Rab acceptor 1 domain family member 3 (PRAF3) is involved in the regulation of many cellular processes including apoptosis, migration and invasion. This study was conducted to investigate the effect...
-
Article
Open AccessElevated C1orf63 expression is correlated with CDK10 and predicts better outcome for advanced breast cancers: a retrospective study
Chromosome 1 open reading frame 63 (C1orf63) is located on the distal short arm of chromosome 1, whose allelic loss has been observed in several human cancers. C1orf63 has been reported to be up-regulated in I...
-
Article
Open AccessPrognostic impact of IKZF1 deletion in adults with common B-cell acute lymphoblastic leukemia
Interrogate the impact of IKZF1 deletion on therapy-outcomes of adults with common B-cell acute lymphoblastic leukemia.
-
Article
Open AccessExpression of AE1/p16 promoted degradation of AE2 in gastric cancer cells
Human anion exchanger 1 and 2 (AE1 and AE2) mediate the exchange of Cl−/HCO3 − across the plasma membrane and regulate intracellular pH (pHi). AE1 is specifically expressed on the surfa...
-
Article
Open AccessDevelopment of a risk-stratification scoring system for predicting lymphovascular invasion in breast cancer
Lymphovascular invasion (LVI) is a vital risk factor for prognosis across cancers. We aimed to develop a scoring system for stratifying LVI risk in patients with breast cancer.
-
Article
Open AccessDisease-free survival as a surrogate endpoint for overall survival in adjuvant trials of pancreatic cancer: a meta-analysis of 20 randomized controlled trials
We aimed to assess whether disease-free survival (DFS) could serve as a reliable surrogate endpoint for overall survival (OS) in adjuvant trials of pancreatic cancer.
-
Article
Open AccessPalliative Gastrectomy versus Gastrojejunostomy for advanced Gastric cancer with outlet obstruction: a propensity score matching analysis
Gastric outlet obstruction (GOO) is a late complication of advanced gastric cancer, and it is controversial how to select the therapeutic strategies: gastrojejunostomy and palliative gastrectomy? Therefore, th...
-
Article
Open AccessDefinitive carbon ion radiotherapy for tracheobronchial adenoid cystic carcinoma: a preliminary report
Tracheobronchial adenoid cystic carcinoma (TACC) is a rare tumour. About one-third of patients miss their chance of surgery or complete resection as it is mostly detected in the advanced stage; hence, photon r...
-
Article
Open AccessTumor residue in patients with stage II–IVA nasopharyngeal carcinoma who received intensity-modulated radiation therapy: development and validation of a prediction nomogram integrating postradiotherapy plasma Epstein–Barr virus deoxyribonucleic acid, clinical stage, and radiotherapy dose
To develop and validate a predictive nomogram for tumor residue 3–6 months after treatment based on postradiotherapy plasma Epstein–Barr virus (EBV) deoxyribonucleic acid (DNA), clinical stage, and radiotherap...
-
Article
Open AccessPredicting the outcomes of hepatocellular carcinoma downstaging with the use of clinical and radiomics features
Downstaging of hepatocellular carcinoma (HCC) makes it possible for patients beyond the criteria to have the chance of liver transplantation (LT) and improved outcomes. Thus, a procedure to predict the prognos...
-
Article
Open AccessDynamic genomic changes in methotrexate-resistant human cancer cell lines beyond DHFR amplification suggest potential new targets for preventing drug resistance
Although DHFR gene amplification has long been known as a major mechanism for methotrexate (MTX) resistance in cancer, the early changes and detailed development of the resistance are not yet fully understood.